J&J Says It Plans to End Covid-19 Vaccine Supply Deal With Emergent BioSolutions

Johnson & Johnson said Monday it planned to terminate its Covid-19 vaccine supply deal with contract manufacturer Emergent BioSolutions Inc., as both companies accused each other of breaching the agreement. J&J informed Emergent last week of its plan to terminate the 2020 manufacturing agreement “based on Emergent’s breaches, including failure to supply Covid-19 vaccine drug substance,” J&J said in a written statement. J&J provided a formal notice of termination and breach to Emergent on Monday, J&J said. The contract disclosure Monday came after Emergent BioSolutions said in a securities filing that it had sent a notice of material breach of the agreement to J&J.